EUVIMEDEUVIMED entdecken
Crossref

Availability of medications for opioid use disorder and hepatitis C services in New York state jails: The New York state integrated jail survey

Lindsey R Riback, Elham Pourtaher, Shannon Mason, Kirsten Rowe, Narelle Ellendon, Matthew Fallico, Colleen Flanigan, Matthew J Akiyama

Public Health · 2026-08 · 257 · 106372

DOI: 10.1016/j.puhe.2026.106372 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Public Health, 2026-08. Verfasst von Lindsey R Riback und 7 weiteren Autor:innen. Beteiligte Einrichtung: Albert Einstein College of Medicine, Montefiore Medical Center, New York, United States. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Hepatitis C, Jails, Opiate Substitution Treatment. Die Arbeit nennt 35 Literaturangaben. Gefördert von: National Institute on Minority Health and Health Disparities, New York State Economic Development Council, National Institute on Drug Abuse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: There is a significant knowledge gap regarding medication for opioid use disorder (MOUD) and hepatitis C virus (HCV) service provision in U.S. jails. To address this gap, characterized screening, treatment, and discharge planning capacity for OUD and HCV in New York State (NYS) jails outside of New York City. STUDY DESIGN: Cross-sectional study. METHODS: Between August and September 2022, 46 of 58 (80%) NYS jails completed a NYS Department of Health survey to determine jails' capacities to implement MOUD and capacity to screen, test and treat HCV. Surveys were completed prior to the October 2022 statewide mandate deadline to provide MOUD in jails. RESULTS: Most (90%) NYS jails reported offering MOUD care continuation for individuals entering their facilities and 88% offered MOUD initiation. Naltrexone was most frequently used for initiation (67%) and buprenorphine for continuation (79%). Self-reported staff capacity to provide HCV screening was high (89%), yet 41% offered routine opt-in HCV screening and only 15% offered opt-out. Most facilities (84%) continued HCV treatment, though only 29% initiated treatment for newly diagnosed individuals. Although half of facilities (51%) had referral agreements with a community provider to facilitate post-release linkage, limited rapid test kits and education resources were barriers to jail-based HCV services. CONCLUSIONS: MOUD availability in NYS jails is promising, but limited HCV service availability suggests support is needed to overcome financial and structural barriers. Strategies such as universal opt-out testing at intake, and task shifting jail-based discharge planning from staff to patient/peer navigators could significantly improve care in jail settings and during reentry.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Opioid-Related DisordersHepatitis CJailsOpiate Substitution TreatmentHealth Services AccessibilityHumansNew YorkCross-Sectional StudiesBuprenorphineHealth Services for PrisonersNaltrexone

Stichwörter der Autor:innen

Hepatitis C (HCV)JailMedication for opioid use disorder (MOUD)buprenorphinemethadonesubstance use disorder (SUD)

Substanzen

BuprenorphineNaltrexone

Autor:innen und Institutionen

  • Albert Einstein College of Medicine, Montefiore Medical Center, New York, United States.
  • AIDS Institute, New York State Department of Health, New York, United States.
  • AIDS Institute, New York State Department of Health, New York, United States. Electronic address: colleen.flanigan@health.ny.gov.
  • Albert Einstein College of Medicine, Montefiore Medical Center, New York, United States. Electronic address: matthew.akiyama@einsteinmed.edu.

Förderung

  • National Institute on Minority Health and Health Disparities
  • New York State Economic Development Council
  • National Institute on Drug Abuse

Zitieren

APA

Riback, L. R., Pourtaher, E., Mason, S., Rowe, K., Ellendon, N., Fallico, M., Flanigan, C., & Akiyama, M. J. (2026). Availability of medications for opioid use disorder and hepatitis C services in New York state jails: The New York state integrated jail survey. Public Health, 257, 106372. https://doi.org/10.1016/j.puhe.2026.106372

Vancouver

Riback LR, Pourtaher E, Mason S, Rowe K, Ellendon N, Fallico M, et al. Availability of medications for opioid use disorder and hepatitis C services in New York state jails: The New York state integrated jail survey. Public Health. 2026;257:106372. doi:10.1016/j.puhe.2026.106372

BibTeX
@article{Riback2026,
  author = {Riback, Lindsey R and Pourtaher, Elham and Mason, Shannon and Rowe, Kirsten and Ellendon, Narelle and Fallico, Matthew and Flanigan, Colleen and Akiyama, Matthew J},
  title = {Availability of medications for opioid use disorder and hepatitis C services in New York state jails: The New York state integrated jail survey},
  journal = {Public Health},
  year = {2026},
  volume = {257},
  pages = {106372},
  doi = {10.1016/j.puhe.2026.106372}
}
Kostenlos starten →